Key Takeaways
- Barclays raised its AbbVie price target to $335 from $325 on Nov. 16 and kept its Overweight rating, after a run that has the stock up 27% in a year.
- AbbVie’s third quarter backed the bulls: revenue rose 10.3%, Skyrizi and Rinvoq each grew more than 20%, and management raised its 2026 earnings guidance.
- Barclays’ target implies 21x forward earnings, above AbbVie’s five-year peak of just under 20x. Meanwhile, analysts’ 2027 earnings estimate has edged down over the past three months.
- The Street’s $312 average target looks like the more realistic 12-month landing, and fourth-quarter results with 2027 guidance in early February are the next test.
AbbVie (ABBV) is up 27% over the past year and closed at $294.55 on Nov. 16, just below its record close of $295.03 three days earlier. Barclays still sees room to run. On Nov. 16, analyst Emily Field raised the firm’s price target to $335 from $325 and kept an Overweight rating. That’s 14% above Monday’s close.
Skyrizi and Rinvoq keep beating the plan
Barclays’ raise follows AbbVie’s Oct. 30 third-quarter report, and it’s easy to see why. Revenue rose 10.3% to $17.4 billion, led by Skyrizi at $5.78 billion (up 22.7%) and Rinvoq at $2.71 billion (up 23.9%). Management raised its 2026 adjusted EPS guidance to $13.95 -$13.99, from $13.76 -$13.96, and raised the quarterly dividend 5.2%.
New rival pills haven’t slowed Skyrizi, either. Chief Commercial Officer Jeff Stewart said on the call that “recent oral competition is not having a substantive impact on our in-play patient share.” Skyrizi is still taking roughly one of every two new or switching psoriasis patients.
Barclays has company at the high end
Barclays’ raise was one of many after the report. Morgan Stanley went to $346, Wells Fargo to $340, and Canaccord to $338, while Citi and UBS kept Neutral ratings with $295 targets. Barclays’ $335 sits 7% above the $312 consensus target, so Field is more bullish than most.
TIKR tracks 29 analysts on AbbVie. How many say “Buy”?
See the full breakdown of Buy, Hold, and Sell ratings on AbbVie, along with Wall Street’s revenue and earnings estimates, all in one place. More than 500,000 investors use TIKR to research stocks like this one. See AbbVie’s Analyst Ratings
Can AbbVie grow into $335?
Wall Street has chased the stock all year. The average target among the 26 analysts who set one on AbbVie climbed from $242 a year ago to $312 by Nov. 13:

The earnings behind those targets look solid. Analysts expect normalized EPS of $13.98 this year, up from $10.00 in fiscal 2025, and $17.99 by fiscal 2028:

The third-quarter beat didn’t lift those estimates, though: the 2027 figure has edged down to $16.20 from $16.28 three months ago. AbbVie’s own guidance didn’t help, since its fourth-quarter adjusted EPS range of 3.83-3.87 came in below the $3.93 FactSet consensus.
And investors already pay up for those earnings. AbbVie trades at about 19x forward earnings, against a five-year average of 14x and a peak just under 20x in October 2025:

Divide Barclays’ $335 by the $15.73 a share analysts expect AbbVie to earn over the next 12 months, and you get 21x. That’s higher than at any point in the past five years. 2027 also brings real headwinds: management expects its Apogee Therapeutics purchase to cut adjusted EPS that year by about $0.46, and Medicare’s set price for Vraylar takes effect.
$312 looks more realistic than $335
AbbVie’s business has earned the credit. But Barclays’ target needs a multiple the stock hasn’t seen in five years, on 2027 estimates that have slipped since the summer. If Skyrizi and Rinvoq keep beating the plan, the stock can climb with its earnings, and the Street’s $312 average is the likelier 12-month landing.
The next test comes in early February, when AbbVie reports its fourth quarter and gives its first 2027 guidance. CEO Rob Michael promised “top-tier growth again next year” on the call. If AbbVie guides to that despite Apogee and Vraylar, analysts will have reason to raise their numbers, and $335 will look far more reasonable.
So what is AbbVie stock actually worth?
TIKR lets you forecast the future price of any stock in less than a minute. Just enter a few assumptions into TIKR’s valuation model and see what AbbVie could be worth. Start from Wall Street consensus estimates, or adjust the inputs to reflect your own view of the business. It’s free to use.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any of the stocks mentioned. Thank you for reading, and happy investing!